ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2134

Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2101

LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2309

Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2340

Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1808

Lightsheet imaging with 3D analysis for wholistic assessment of synovial lymphatic vasculature within joints of murine models of arthritis

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2063

Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2276

Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2362

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2279

Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2352

Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2454

Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1958

Longitudinal analysis on imaging outcomes: should we use the individual scores from multiple readers or rather the consensus or average of readers?

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2447

Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1920

Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 2259

Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].